COVID-19 Vaccinated PBMCs (Time Series)

$2,500.00$3,000.00

Source:

Peripheral Blood

Status:

Healthy

Viability:

>95% by flow cytometry

For a custom order, contact us or click here to customize.

Select Format

Please specify a format to review quotes

20 x 106 1150P
Pfizer - Pre Vacc, Post Vacc (Dose 1), Post Vacc (Dose 2)
$3,000.00 Cryopreserved
Add to cart
20 x 106 1150M
Moderna - Pre Vacc, Post Vacc (Dose 1), Post Vacc (Dose 2)
$3,000.00 Cryopreserved
Add to cart
20 x 106 1150J
Johnson & Johnson - Pre Vacc, Post Vacc
$2,500.00 Cryopreserved
Add to cart
Total:
SKU:

Description

Product Overview:

Peripheral blood-derived mononuclear cells (PBMCs) are purified from an apheresis leukopak product which contains a highly enriched population of mononuclear cells when compared to buffy coat or whole blood.

COVID-19 vaccinated PBMCs are isolated from a leukopak collected from consented healthy donors with no prior COVID-19 infection who have received a COVID-19 vaccine from Pfizer, Moderna, or Johnson & Johnson (J&J). The COVID-19 vaccinated PBMCs (time series) are collected at the following time points:

  1. prior to COVID-19 vaccination
  2. 10-30 days after the first vaccine administration
  3. 10-30 days after the second vaccine administration (when applicable)

The COVID-19 vaccinated PBMCs are purified by density gradient centrifugation and are available in cryopreserved format.

COVID-19 vaccinated PBMCs can be used as a unique research tool to investigate the immune response within our body to understand the deadly pathology of COVID-19 and to examine vaccine efficacy between different population subgroups.

Storage Conditions:

Prepare PBMCs for long-term storage in liquid nitrogen vapor phase or thaw for use. Storage in liquid phase nitrogen is NOT recommended. Short-term storage of cells (less than 2 weeks) at -80°C is acceptable but should be minimized to ensure maximum stability. Once thawed, samples must be used immediately.

Testing:

Donors are tested for the blood borne pathogens HIV-1 and 2, Hepatitis B, Hepatitis C and HTLV-1.

Increased IFN-g Secretion by Post-Vaccine PBMC In Response to Recombinant S1 Protein from SARS-CoV-2. COVID-19 Vaccinated PBMCs show a heightened response to varying concentrations of SARS-CoV-2 recombinant Spike S1 protein, as measured by IFN-g expression 2 weeks after the second vaccine administration (Post-2X) when compared to the pre-vaccine PBMCs. The PBMCs were isolated from apheresis drawn prior to vaccination (Pre-Vaccine) and 2 weeks after the second vaccine administration (Post-2X Vaccine). 100K PBMCs, from each of the pre and post vaccine timepoints, were incubated in 200 mL X-VIVO-15 media (Lonza, Walkersville, MD) +/- different concentrations of SARS-CoV-2 recombinant Spike S1 protein (Origene, Rockville, MD) in a 37oC, 5% CO2 humidified incubator.  Each condition was performed in triplicates.  Supernatants were harvested after 4 days of culture and analyzed for interferon gamma (IFN-g) using the Meso Scale Discovery (MSD, Rockville, MD) multiplex system.  IFN-g concentrations are presented against final concentration of recombinant S1 protein.

Blog

Could MSCs Treat Patients Severely Ill from COVID-19?

Exploring CAR-T and TCR-T Therapies for COVID-19 Treatment

T Cells Could Play a Protective Role Against COVID-19

Cryopreserved T Cells Hold Answers to COVID-19 Immunity

Certificate of Analysis

Cryopreserved Peripheral Blood COVID-19 Vaccinated PBMC

Protocols

How to Thaw COVID-19 Vaccinated PBMCs